Patty said that for caregivers, it’s essential to lean on the care team for information specific to the procedure, medication ...

Cleveland Browns owners recently made a large donation for cancer research. Dee Haslam lives daily with a rare blood cancer ...

BeOne Medicines has entered the BCL-2 arena, securing an FDA green light for Beqalzi that carves out a unique piece of territory ahead of a potential broader clash with market leader Venclexta. The ...

FDA accelerated approval covers relapsed/refractory MCL after ≥2 lines including a BTK inhibitor, positioning sonrotoclax as ...

BeOne Medicines’ sonrotoclax receives US FDA approval as first and only BCL2 inhibitor for R/R mantle cell lymphoma: San Carlos, California Saturday, May 16, 2026, 14:00 Hrs [IS ...

In preclinical studies of CSU, Bexobrutideg demonstrates potent BTK degradation across key immune cell types and enhanced suppression of ...

Management attributes the increased net loss primarily to non-cash fair value adjustments of warrant liabilities from the ...

Detailed price information for Beone Medicines Ltd (ONC-Q) from The Globe and Mail including charting and trades.

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today ...

BEQALZI™ (sonrotoclax) is a BCL-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) after at least two lines of systemic therapy, ...

Accelerated approval of sonrotoclax establishes a targeted BCL2 option in post–BTK inhibitor relapsed/refractory mantle cell lymphoma, a setting with limited effective salvage therapies and poor ...